The overall 5-year survival rate for MM has been improved to 49–56% due to novel therapeutics, including proteasome inhibitors [53] and IMiDs, the latter, which kill transformed cells by targeting proteins for degradation through binding to CRBN, the substrate receptor of the CRL4-CRBN E3 ubiquitin ligase [54]. Here, IL17RB is linked to Miyoshi myopathy.